In Brief: Astra
Executive Summary
Astra: Company sued Rhone-Poulenc Rorer and Centeon Feb. 12 in Worcester, Mass. federal court for failing to supply three I.V. vitamin products: MVI-12, MVI Pediatric, and Aquasol A. RPR/Centeon has been responsible for manufacturing since 1990, when Astra purchased rights to the I.V. vitamins from RPR. The suit claims that RPR/Centeon has been unable to supply the requisite amounts of the products since 1993, resulting in a current nationwide shortage. Astra maintained it realized a sales loss of $22 mil. in 1997 for the MVI products...
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth